

BBI DIAGNOSTICS GROUP 2 PLC

UNAUDITED ANNUAL REPORT

FOR THE YEAR ENDED 31 DECEMBER 2017

Registered number: 08741927

THURSDAY



A750UMUZ

A13

10/05/2018

#296

COMPANIES HOUSE

CONTENTS

	Page
COMPANY INFORMATION	2
STRATEGIC REPORT	3
DIRECTORS' REPORT	4
INCOME STATEMENT	5
STATEMENT OF FINANCIAL POSITION	6
STATEMENT OF CHANGES IN EQUITY	7
NOTES TO THE FINANCIAL STATEMENTS	8 - 10

DIRECTORS AND OTHER INFORMATION

Board of Directors

Gregory Tazalla
Benjamin Edward Oosterbaan
Brian Bernard Yoor

Company secretary

David Andrew Bond

Registered Office

Clearblue Innovation Centre
Priory Business Park
Stannard Way
Bedford
Bedfordshire MK44 3UP
United Kingdom

Registered Number: 08741927

**STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2017**

Introduction

The Directors present their Strategic Report of BBI Diagnostics Group 2 plc (the "Company") for the year ended 31 December 2017.

Business review

The Company did not trade or enter into any commercial transactions during the year and accordingly no review of the business is presented.

Principal risks and uncertainties

As the Company currently has no commercial activity, it is not exposed to any significant risk or uncertainty.

Key performance indicators

As the Company did not trade or enter into any commercial transactions during the year, no analysis of key performance indicators is available.

This report was approved by the board on 8th May 2018 and signed on its behalf.


Benjamin Oosterbaan

DIRECTOR

**DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2017**

The Directors present their report and the financial statements for the year ended 31 December 2017.

Results and dividends

The profit for the year, after taxation, amounted to £NIL (2016 - £NIL)

The Directors do not propose the payment of a dividend (2016 – £NIL)

Directors

The Directors who served during the year were:

Douglas Barry (resigned 3rd October 2017)

John Bridgen (resigned 3rd October 2017)

Ellen V Chiniara (resigned 3rd October 2017)

Gregory Tazalla (appointed 3rd October 2017)

Benjamin Edward Oosterbaan (appointed 3rd October 2017)

Brian Bernard Yoor (appointed 3rd October 2017)

Future developments

The Company does not anticipate undertaking any activities in the foreseeable future.

Financial instruments

The only financial instrument held by the Company is an intercompany balance receivable from its parent company. There are no significant risks attaching to this balance that require active management by the Directors of the Company.

This report was approved by the board on 8th May 2018 and signed on its behalf.



Benjamin Oosterbaan

DIRECTOR

**INCOME STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2017**

The Company has not traded during the year or the preceding financial year. During these periods, the Company received no income and incurred no expenditure and therefore made neither profit or loss.

REGISTERED NUMBER: 08741927**STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2017**

		2017 £'000	2016 £'000
Current assets			
Debtors: amounts falling due within one year	4	<u>12,500</u>	<u>12,500</u>
Total assets less current liabilities		<u>12,500</u>	<u>12,500</u>
Capital and reserves			
Called up share capital	5	<u>12,500</u>	<u>12,500</u>

For the year ended 31 December 2017 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and for preparing financial statements which give a true and fair view of the state of affairs of the Company as at the end of the financial year and of its profit or loss for the financial year, in accordance with the requirements of sections 394 and 395 of the Act and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the Company.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 8th May 2018



Benjamin Oosterbaan
Director

The notes on pages 8 to 10 form part of these financial statements.

BBI DIAGNOSTICS GROUP 2 PLC

STATEMENT OF CHANGES IN EQUITY
For the financial year ended 31 December 2017

	Called up share capital £	Total £
Balance as at 1 January 2016	12,500	12,500
Profit for the year	-	-
Total comprehensive income for the financial year	-	-
Balance as at 31 December 2016	<u>12,500</u>	<u>12,500</u>
Balance as at 1 January 2017	12,500	12,500
Profit for the financial year	-	-
Total comprehensive income for the financial year	-	-
Balance as at 31 December 2017	<u>12,500</u>	<u>12,500</u>

The notes on pages 8 to 10 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

1 General information

BBI Diagnostics Group 2 plc is a dormant company incorporated in England, registered number 08741927.

The address of its registered office is Clearblue Innovation Centre Stannard Way, Priory Business Park, Bedford, MK44 3UP.

2 Accounting Policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

a. Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland and the Companies Act 2006.

b. Financial reporting standard 102 – reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 4 Statement of Financial Position paragraph 4.12(a)(iv) ;
- the requirements of Section 7 Statement of Cash Flows;
- the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirements of Section 11 Financial Instruments paragraphs 11.39 to 11.48A;
- the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.29;
- the requirements of Section 33 Related Party Disclosures paragraph 33 .7.

This information is included in the consolidated financial statements of Abbott Laboratories as at 31 December 2017 and these financial statements may be obtained from: 100 Abbott Park Road, Abbott Park, Illinois, USA. 60064-6400

NOTES TO THE FINANCIAL STATEMENTS - continued

2 Accounting Policies - continued

c. Financial instruments

The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like other accounts receivable.

Debt instruments (other than those wholly repayable or receivable within one year) , including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Income Statement.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

NOTES TO THE FINANCIAL STATEMENTS - continued

3 Employees

The Average monthly number of employees, including the Directors, during the year was as follows:

	2017	2016
	No.	No.
Directors	<u>3</u>	<u>3</u>

The Directors did not receive any remuneration in respect of their services provided to the Company in the year (2016 - £NIL)

4 Debtors

	2017	2016
	£'000	£'000
Amounts owed by group undertakings	<u>12,500</u>	<u>12,500</u>

5 Share capital

	2016 and 2017 Number	2016 and 2017 £'000
Allotted, called up and fully paid:		
At 1 January and 31 December	<u>125,000</u>	<u>12,500</u>

6 Ultimate holding company and controlling party

The company's immediate parent undertaking is Alere BBI Holdings Limited, a company incorporated in England and Wales.

The company's ultimate parent undertaking and controlling party up until 2nd October 2017 was Alere Inc. On 3rd October 2017 Alere Inc. entered into a Merger agreement with Abbott Laboratories, a company incorporated in the United States of America (NYSE: ABT), under which Abbott Laboratories acquired Alere Inc. Alere Inc. survived the merger as a subsidiary of Abbott Laboratories.

At the reporting date, Abbott Laboratories is the smallest and largest company which prepares consolidated financial statements. Copies of the consolidated financial statements can be obtained from: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois, USA. 60064-6400.